{"id":"immunosuppressive-agents","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL4298067","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class rather than a single entity. Immunosuppressive agents work through various mechanisms including T-cell inhibition (calcineurin inhibitors, mTOR inhibitors), lymphocyte depletion (monoclonal antibodies), or costimulation blockade. They are used to prevent organ transplant rejection and treat autoimmune conditions by reducing pathogenic immune responses.","oneSentence":"Immunosuppressive agents inhibit or dampen immune system activation to prevent rejection or reduce autoimmune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:43.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune disease management"}]},"trialDetails":[{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05826535","phase":"PHASE1, PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":"Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":270},{"nctId":"NCT00001352","phase":"","title":"Fungal Infection Susceptibility","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-04-01","conditions":"Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis","enrollment":800},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT02199145","phase":"NA","title":"Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-07-17","conditions":"Membranous Nephropathy","enrollment":52},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT07383649","phase":"PHASE2","title":"Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03","conditions":"Brain Cancer Metastatic, CMV Viremia","enrollment":28},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT03323476","phase":"PHASE3","title":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2018-02-02","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease","enrollment":136},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT01729455","phase":"","title":"Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-21","conditions":"Systemic Lupus Erythematosus","enrollment":3138},{"nctId":"NCT07486206","phase":"NA","title":"Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","status":"RECRUITING","sponsor":"Hospital de Granollers","startDate":"2026-03-09","conditions":"Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)","enrollment":152},{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT03520647","phase":"PHASE2","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2019-02-19","conditions":"Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":56},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT03835312","phase":"NA","title":"Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-02-20","conditions":"Diabetes Mellitus, Type 1, Immunologic Deficiency Syndromes","enrollment":50},{"nctId":"NCT06962800","phase":"PHASE3","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-05-22","conditions":"Primary Membranous Nephropathy","enrollment":180},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04207580","phase":"","title":"A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2020-03-13","conditions":"Idiopathic Nephrotic Syndrome","enrollment":1180},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25},{"nctId":"NCT03232268","phase":"PHASE1","title":"HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2018-03-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":25},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT06254248","phase":"PHASE2","title":"Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-22","conditions":"Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment","enrollment":50},{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT05894512","phase":"","title":"Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-06-01","conditions":"Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced","enrollment":44},{"nctId":"NCT07447388","phase":"NA","title":"Development, Pilot Testing and Evaluation of the Effectiveness of Immunosuppressive Medication Adherence Care Bundle in Patients Undergoing Solid Organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Hacettepe University","startDate":"2026-03-01","conditions":"Transplant Patients","enrollment":100},{"nctId":"NCT06981767","phase":"PHASE2","title":"Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-02-18","conditions":"Oral Lichen Planus","enrollment":42},{"nctId":"NCT05873205","phase":"PHASE2","title":"Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-07-21","conditions":"Blood Cancer, Refractory Immune Cytopenias","enrollment":12},{"nctId":"NCT01555892","phase":"PHASE1","title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2013-01-14","conditions":"Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease","enrollment":136},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT07219121","phase":"PHASE4","title":"Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis","status":"RECRUITING","sponsor":"Travere Therapeutics, Inc.","startDate":"2025-10-07","conditions":"Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis","enrollment":20},{"nctId":"NCT06879106","phase":"NA","title":"Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation","status":"COMPLETED","sponsor":"Bitlis Eren University","startDate":"2025-02-15","conditions":"Liver Transplant; Complications, Immunosuppression, Compliance, Treatment","enrollment":140},{"nctId":"NCT07430449","phase":"NA","title":"The Effect of Education Given According to Roy's Adaptation Model","status":"COMPLETED","sponsor":"Trakya University","startDate":"2024-11-01","conditions":"Chronic Kidney Disease, Immunosuppressive Therapy","enrollment":78},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT05799755","phase":"PHASE4","title":"Myositis Interstitial Lung Disease Nintedanib Trial","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2023-08-01","conditions":"Myositis Associated Interstitial Lund Disease (MA-ILD)","enrollment":49},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT07415083","phase":"","title":"A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-21","conditions":"Aplastic Anemia","enrollment":13},{"nctId":"NCT06902896","phase":"PHASE1","title":"Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Dilated Cardiomyopathy (DCM), Heart Failure","enrollment":9},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT02201576","phase":"PHASE2","title":"Bortezomib in Rejection of Kidney Transplants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-11","conditions":"Chronic Antibody-mediated Transplant Rejection","enrollment":60},{"nctId":"NCT07258524","phase":"","title":"PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2026-01-28","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":120},{"nctId":"NCT06138379","phase":"NA","title":"Video-supported Training in Line With the Health Belief Model","status":"COMPLETED","sponsor":"Inonu University","startDate":"2023-12-01","conditions":"Education","enrollment":90},{"nctId":"NCT07089420","phase":"","title":"ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects","status":"RECRUITING","sponsor":"American Laboratory Products Company","startDate":"2025-07-07","conditions":"IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD)","enrollment":120},{"nctId":"NCT02203396","phase":"PHASE2","title":"A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2014-08","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT05698745","phase":"","title":"Immunological Characteristics of Preclinical IBD","status":"RECRUITING","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2024-06-01","conditions":"Crohn Disease, Ulcerative Colitis, IBD","enrollment":450},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT04877288","phase":"PHASE3","title":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-21","conditions":"Renal Allograft Recipients","enrollment":102},{"nctId":"NCT07382375","phase":"NA","title":"AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Medical University","startDate":"2027-12-31","conditions":"Aortic Aneurysm and Dissection","enrollment":300},{"nctId":"NCT07380659","phase":"PHASE1","title":"Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-20","conditions":"Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction","enrollment":18},{"nctId":"NCT04182984","phase":"","title":"TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2019-11-04","conditions":"Ocular Myasthenia Gravis","enrollment":200},{"nctId":"NCT06193889","phase":"PHASE2, PHASE3","title":"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-08-28","conditions":"Myasthenia Gravis, Generalized Myasthenia Gravis","enrollment":66},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT06072482","phase":"PHASE4","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-02-07","conditions":"Antineutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":300},{"nctId":"NCT04262843","phase":"PHASE2","title":"Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-02-07","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT07364123","phase":"NA","title":"Kidney Transplant Immunosuppressive Therapy Adherence Trial (KITE)","status":"NOT_YET_RECRUITING","sponsor":"University of Gaziantep","startDate":"2026-01-05","conditions":"Kidney Transplantation, Medication Non-Adherence, Immunosuppressive Therapy","enrollment":60},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT06084780","phase":"PHASE2","title":"Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-02","conditions":"Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei","enrollment":20},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT07214818","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-11-15","conditions":"Nephrotic Syndrome","enrollment":75},{"nctId":"NCT02979873","phase":"PHASE2","title":"Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-12-19","conditions":"Severe Aplastic Anemia","enrollment":84},{"nctId":"NCT07343401","phase":"","title":"Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2025-08-01","conditions":"Sarcoidosis Lung","enrollment":40},{"nctId":"NCT00033475","phase":"PHASE3","title":"Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2001-03-01","conditions":"Lymphoproliferative Disorder","enrollment":50},{"nctId":"NCT07343661","phase":"PHASE4","title":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","status":"ENROLLING_BY_INVITATION","sponsor":"Azienda Ospedaliero Universitaria di Cagliari","startDate":"2025-10-17","conditions":"EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma","enrollment":90},{"nctId":"NCT04180085","phase":"PHASE2","title":"Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-06","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04789070","phase":"PHASE3","title":"Phase III Trial of Sirolimus in IBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-07-01","conditions":"Inclusion Body Myositis","enrollment":140},{"nctId":"NCT04545762","phase":"PHASE1","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"C. Babis Andreadis","startDate":"2020-09-11","conditions":"Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT07329959","phase":"PHASE1","title":"CAR-DC for End-Stage IPF","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-02-01","conditions":"Idiopathic Pulmonary Fibrosis(IPF)","enrollment":8},{"nctId":"NCT07325357","phase":"PHASE4","title":"Effect of Pirfenidone on TA Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-20","conditions":"Takayasu Arteritis","enrollment":92},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT07319793","phase":"NA","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":200},{"nctId":"NCT06219616","phase":"NA","title":"Prediction of BK Virus Reactivation in Kidney Transplant Recipient","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2023-05-01","conditions":"Kidney Transplant Infection, BK Virus Infection, BK Virus Nephropathy","enrollment":80},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":51},{"nctId":"NCT02990286","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-01-20","conditions":"Lung Disease, Interstitial","enrollment":122},{"nctId":"NCT07309588","phase":"PHASE1, PHASE2","title":"Hyaluronic Acid in the Treatment of Hyposalivation","status":"ENROLLING_BY_INVITATION","sponsor":"Poznan University of Medical Sciences","startDate":"2025-07-01","conditions":"Xerostomia Due to Hyposecretion of Salivary Gland","enrollment":100},{"nctId":"NCT07288918","phase":"NA","title":"The Effect of Education on Quality of Life, Adherence to Immunosuppressive Therapy and Symptom Control in Organ Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Ondokuz Mayıs University","startDate":"2025-12-10","conditions":"Organ Transplantation, Mobile Applications, Nursing","enrollment":108},{"nctId":"NCT06834191","phase":"","title":"Relationship Between Immunosuppressive Treatment Status and Clinical Course of Parkinson's Disease","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-03-01","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT07275632","phase":"PHASE1, PHASE2","title":"The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-12-10","conditions":"Delayed Graft Function, Kidney Transplantation","enrollment":47}],"_emaApprovals":[],"_faersSignals":[{"count":17,"reaction":"PYREXIA"},{"count":15,"reaction":"PREGNANCY"},{"count":13,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":12,"reaction":"ABORTION SPONTANEOUS"},{"count":12,"reaction":"BLOOD PRESSURE DECREASED"},{"count":11,"reaction":"NEPHROGENIC SYSTEMIC FIBROSIS"},{"count":11,"reaction":"PAIN"},{"count":9,"reaction":"ARTHRALGIA"},{"count":9,"reaction":"DIARRHOEA"},{"count":9,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf, Cellcept","Immunosuppressive group","Multi-target immunosuppressive therapy","Immunosuppressant","Prednisolone"],"phase":"phase_3","status":"active","brandName":"Immunosuppressive Agents","genericName":"Immunosuppressive Agents","companyName":"Loma Linda University","companyId":"loma-linda-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Immunosuppressive agents inhibit or dampen immune system activation to prevent rejection or reduce autoimmune responses. Used for Organ transplant rejection prevention, Autoimmune disease management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}